Table 1.
Demographics and treatments used in nCFB patients at enrolment.
| Patient Demographics (n = 29) | Decliners (n = 11) | Stables (n = 18) | Total (n = 29) |
|---|---|---|---|
| Median Age at Study Enrolment (IQR) | 63 (39–70) | 57 (50–68) | 60 (48–69) |
| Median FEV1 at enrolment (% predicted) (IQR) | 71 (45–93) | 53 (39–67) | 55% (40.5–74) |
| Respiratory Comorbidities | |||
| Sinusitis | 5 (45%) | 10 (56%) | 15 (52%) |
| Asthma | 1 (9%) | 3 (17%) | 4 (14%) |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 2 (11%) | 2 (7%) |
| Treatments Recorded During Sample Collection | |||
| Inhaled corticosteroids | 7 (64%) | 14 (78%) | 21 (72%) |
| Long-acting beta-agonists (LABA) | 6 (55%) | 14 (78%) | 20 (69%) |
| Long-acting muscarinic antagonist (LAMA) | 1 (9%) | 8 (44%) | 9 (31%) |
| Short-acting beta-agonists (SABA) | 6 (55%) | 12 (67%) | 18 (62%) |
| Ipratropium bromide | 3 (27%) | 7 (39%) | 10 (34%) |
| Saline | 2 (18%) | 4 (22%) | 6 (21%) |
| Proton-pump inhibitors | 1 (9%) | 2 (11%) | 3 (10%) |
| H2-receptor antagonists | 1 (9%) | 1 (6%) | 2 (7%) |
| Cultured Pathogens | |||
| Pseudomonas aeruginosa | 6 (55%) | 10 (56%) | 16 (55%) |
| Haemophilus influenzae | 4 (36%) | 4 (22%) | 8 (28%) |
| Staphylococcus aureus | 3 (27%) | 5 (28%) | 8 (28%) |
| Moraxella catarrhalis | 2 (18%) | 1 (6%) | 3 (10%) |
| Streptococcus pneumoniae | 1 (9%) | 3 (17%) | 4 (14%) |
Inter-quartile Range (IQR) and percent are indicated by the parenthesis.